Live Biotherapeutics Drug Discovery Services for Childhood Asthma
Interest in probiotics is spurred by the recent advances made in understanding the human microbiome and its role in human health. The link between the gut microbiome and human health is becoming increasingly clear. With industry-leading expertise and state-of-the-art technology, Creative Biolabs has pioneered the development of next-generation probiotics (NGPs). Our scientists are committed to providing overall solutions for NGPs discovery, bioprocess development, and good manufacturing practice (GMP) scale-up. We are more than happy to share our experience and help our clients' research in the prevention and treatment of childhood asthma.
Introduction of Childhood Asthma
As the most common chronic disease of childhood in developed countries, asthma is characterized by dyspnoea of an obstructive type which is predominantly expiratory, reversible at least partially, and of varying severity and duration. Recent studies suggest that most asthmatics are diagnosed by the age of five, with symptoms first occurring during infancy and early childhood. Allergy is known to play a significant role in childhood asthma. The prevalence of allergic diseases including asthma has increased significantly over the past 40 years. The reasons for this increase are not known but are under active investigation.
Childhood Asthma and Probiotics
Pre-clinical studies have shown that modifying the microbiota could modulate the global immune response of the host, thus reducing sensitization and allergic inflammation. Many studies have suggested the hypothesis that probiotics might be protective for asthma. Early administration of Lactobacillus reuteri to infants did not result in a reduction of asthma, nor did Lactobacillus rhamnosus HN001 or Lactobacillus paracasei. Better results have been obtained with probiotic bacteria based on in vitro modulation of cytokine production. Bifidobacterium bifidum, Bifidobacterium lactis, and Lactococcus lactis were shown to have a good IL-10-inducing capacity and to exert a significant inhibition of Th2-related cytokines IL-5 and IL-13. However, their beneficial effect does not reach the age of 6 years and there is no primary prevention of asthma. Although there is valid scientific evidence in vitro, there is no sufficient information to support that the use of probiotics is effective in preventing asthma. At this point, it seems necessary to understand more precisely the microbiota composition of healthy humans.
Fig.1 Distribution of common phyla and genera in the airways of healthy and asthmatic subjects. (Hufnagl, 2020)
NGPs Discovery Service at Creative Biolabs
Many probiotics share the same mechanism of action, while strain-specific, species-specific, or genus-specific probiotic effects have also been documented. Although the use of probiotics in prevention as a whole class has widespread in clinical practice, there is no positive recommendation to use specific probiotics for the prevention of asthma. With years of research in probiotics for the prevention of asthma, seasoned scientists at Creative Biolabs figure that only by understanding the microbiota composition more precisely, identifying the specific changes and the specific probiotics, it may be a way to prevent or fight specific dysbiosis of asthma.
Creative Biolabs has gained significant knowledge in the development of NGPs, including probiotic identification, enumeration, contamination, and stability testing. Our comprehensive portfolio fully supports GMP from your microbial start cultures through finished products. Please contact us for more information and a detailed quote.
Reference
-
Hufnagl, K.; et al. Dysbiosis of the gut and lung microbiome has a role in asthma. InSeminars in Immunopathology. 2020, pp. 1-19. Springer Berlin Heidelberg.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Related Services
